Share class: Vaxcyte, Inc.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A1124,636,546121,980,413 ( 97.87 %) 0 97.87 %

Major shareholders: Vaxcyte, Inc.

NameEquities%Valuation
Fidelity Management & Research Co. LLC
12.68 %
15,800,667 12.68 % 1 293 M $
Vanguard Fiduciary Trust Co.
9.179 %
11,440,483 9.179 % 937 M $
Janus Henderson Investors US LLC
8.786 %
10,950,124 8.786 % 896 M $
BlackRock Advisors LLC
8.272 %
10,309,850 8.272 % 844 M $
RA Capital Management LP
6.972 %
8,689,190 6.972 % 711 M $
Capital Research & Management Co. (Global Investors)
3.93 %
4,898,221 3.93 % 401 M $
Wellington Trust Co., NA
3.622 %
4,513,756 3.622 % 369 M $
T. Rowe Price International Ltd.
3.583 %
4,466,137 3.583 % 366 M $
T. Rowe Price Investment Management, Inc.
3.253 %
4,053,828 3.253 % 332 M $
State Street Corp.
2.733 %
3,405,743 2.733 % 279 M $
░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional99.03%
Other7.4%
State Street Corp.2.73%
Individuals0.91%
Polar Capital Holdings Plc0.8%
Raymond James Financial, Inc.0.21%
SEI Investments Co.0.17%
Schweizerische Nationalbank0.14%
Manulife Financial Corp.0.13%
Corebridge Financial, Inc.0.05%

Based on 1000 largest holdings

Geographical origin of shareholders

United States 99.88%
United Kingdom 7.93%
Individuals 0.91%
Norway 0.81%
Denmark 0.61%
Canada 0.59%
Germany 0.24%
Switzerland 0.23%
Luxembourg 0.1%
Australia 0.1%
Ireland 0.06%
Sweden 0.03%
China 0.03%
Singapore 0.02%
South Korea 0.01%
Taiwan 0.01%
Japan 0.01%

Based on 1000 largest holdings

Logo Vaxcyte, Inc.
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Employees
254
More about the company